late-stage trial of its experimental lab-produced antibody treatment against Covid-19 over an unspecified safety concern, the company said."Lilly is supportive of the decision by the independent DSMB (data safety monitoring board) to cautiously ensure the safety of the patients participating in this study," a spokesperson told AFP in a statement.The Phase 3 randomized control trial is a study of hospitalized Covid-19 patients that began in August across more than 50 sites in the United States, Denmark and Singapore with the aim of recruiting 10,000 people.It is sponsored by the US National Institutes of Health.Monoclonal antibody treatments have been making headlines recently after US President Donald Trump credited one therapy, developed.